Skip to main content
Clinical Trials/CTRI/2019/05/019168
CTRI/2019/05/019168
Completed
Phase 2

A clinical study to compare the antihypertensive benefits of Cilnidipine & Azilsartan in T2DM patients. - not applicable

Dr SHAMEEMUNISHA0 sites64 target enrollmentTBD

Overview

Phase
Phase 2
Intervention
Not specified
Conditions
Health Condition 1: -
Sponsor
Dr SHAMEEMUNISHA
Enrollment
64
Status
Completed
Last Updated
3 years ago

Overview

Brief Summary

No summary available.

Registry
who.int
Start Date
TBD
End Date
TBD
Last Updated
3 years ago
Study Type
Interventional

Investigators

Sponsor
Dr SHAMEEMUNISHA

Eligibility Criteria

Inclusion Criteria

  • 1\.Patients with Type 2 Diabetes Mellitus \> 2years duration on medical treatment with newly diagnosed Simple Hypertension (JNC8\)
  • 2\.Male and Female
  • 3\.Age \>40 years
  • 4\.Outpatient from Department of General Medicine.
  • 5\.BMI up to type I obesity (30\-40\)
  • 6\.All DM patients on OHA either single /double/triple/insulin

Exclusion Criteria

  • 1\.Renal dysfunction,
  • 2\.Patients on NSAIDS, STATIN, ASPIRIN, Immunomodulators , alternative medicines
  • 3\.Hepatic dysfunction
  • 4\.Cardiac abnormalities
  • 5\.Pregnancy and lactating women
  • 6\.Inpatients
  • 7\.ICU patients
  • 8\.EMD patients
  • 9\.Serious infections
  • 11\.H/o Smoking,Alcohol

Outcomes

Primary Outcomes

Not specified

Similar Trials